Area of research
Hepatology · Oncology
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, CAR-T cell therapy research, Cholangiocarcinoma and Gallbladder Cancer Studies, and Cancer Mechanisms and Therapy.
Expert consensus on the multidisciplinary diagnosis and treatment of multiple ground glass nodule-like lung cancer (2024 Edition) ∆
Identification of risk and prognostic factors for intrahepatic vascular invasion in patients with hepatocellular carcinoma: a population-based study
Aspartate-β-hydroxylase as a promising prognostic and therapeutic biomarker for HBV-positive hepatocellular carcinoma
Targeting mTORC2/HDAC3 Inhibits Stemness of Liver Cancer Cells Against Glutamine Starvation
Clinical practice guidelines on image-guided thermal ablation of primary and metastatic lung tumors (2022 edition)
TOP2A inhibition reverses drug resistance of hepatocellular carcinoma to regorafenib.
PubMed 2022cited by 28position: last
Transcriptome Profiles Reveal a 12-Signature Metabolic Prediction Model and a Novel Role of Myo-Inositol Oxygenase in the Progression of Prostate Cancer
EGFR activation limits the response of liver cancer to lenvatinib
Expert consensus on thermal ablation therapy of pulmonary subsolid nodules (2021 Edition)
Chinese expert consensus of image-guided irreversible electroporation for pancreatic cancer
Correction to: LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells
[Expert Consensus for Thermal Ablation of Pulmonary Subsolid Nodules (2021 Edition)].
Expert consensus workshop report: Guidelines for thermal ablation of thyroid tumors (2019 edition)
LncRNA TTN-AS1 promotes the progression of cholangiocarcinoma via the miR-320a/neuropilin-1 axis
Silencing <italic>KIF14</italic> reverses acquired resistance to sorafenib in hepatocellular carcinoma
LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells
Integrating high‐throughput microRNA and mRNA expression data to identify risk mRNA signature for pancreatic cancer prognosis
Expert consensus workshop report
Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells
Dual inhibition of Akt and c‐Met as a second‐line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells
Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis
Applying negative pressure wound therapy in associating liver partition and portal vein ligation for staged hepatectomy: A case report
An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells
MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway
Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus
Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma
Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells
Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation
Meloxicam Executes Its Antitumor Effects against Hepatocellular Carcinoma in COX-2- Dependent and -Independent Pathways
Matrine inhibits proliferation and induces apoptosis of human colon cancer LoVo cells by inactivating Akt pathway